Clinical Trial

A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR) advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-28.
Status change: Not Yet Recruiting → Recruiting 2025-11-27
Trial Details
NCT Number NCT07208136
Lead Sponsor Jemincare
Conditions Advanced Solid Tumors
Enrollment 102 participants
Start Date 2025-10-22
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-01